metricas
covid
Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Chromogranin A (CgA) as a biomarker in carcinoid heart disease and NETG1/G2 neur...
Journal Information
Vol. 159. Issue 2.
Pages 85-89 (July 2022)
Share
Share
Download PDF
More article options
Visits
3
Vol. 159. Issue 2.
Pages 85-89 (July 2022)
Brief report
Chromogranin A (CgA) as a biomarker in carcinoid heart disease and NETG1/G2 neuroendocrine neoplasms of the small intestine (SI-NENs) related carcinoid syndrome
Valor de la cromogranina A como biomarcador de enfermedad cardiaca en el síndrome carcinoide asociado a tumores neuroendocrinos del intestino delgado
Visits
3
Sonia J. Konsek-Komorowskaa,
Corresponding author
sonia.konsek@interia.pl

Corresponding author.
, Mariola Pęczkowskab, Agnieszka D. Kolasińska-Ćwikłac, Marek Konkab, Eryk Chrapowickic, Jarosław B. Ćwikład
a Department of Cardiology and Internal Medicine, School of Medicine, University of Warmia and Mazury, 10-082 Olsztyn, Poland
b The Cardinal Stefan Wyszyński National Institute of Cardiology, 04-628 Warsaw, Poland
c MSC Memorial Cancer Centre and Institute – Maria Sklodowska-Curie, 02-034 Warsaw, Poland
d Diagnostic and Therapeutic Center – Gammed, 02-351 Warsaw, Poland
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Abstract
Introduction

Progression of carcinoid syndrome (CS) to carcinoid heart disease (CHD) is difficult to predict. This retrospective analysis evaluates the use of chromogranin A (CgA), a biomarker widely used in the diagnosis of neuroendocrine tumours (NET), in monitoring CS and disease progression.

Patients and methods

108 patients with confirmed CS, selected from a group of 351 patients with neuroendocrine neoplasms of the small intestine (SI-NENs), including NETG1 well 40% and NETG2 60% moderately differentiated NET. CgA concentration was measured during initial diagnosis and clinical follow up in 84 patients, 27 of them subsequently developed CHD. The patient's overall survival (OS) was evaluated using the Kaplan-Meier method.

Results

Patients with CHD, were found to have significantly shorter OS than patients with CS but without CHD (67.22 vs. 73.03 months). Univariate and multivariate analyses revealed that initial high concentration of CgA and/or increased concentration of CgA is significantly associated with decreased median OS in patients with CS (p<0.05).

Conclusion

CgA has potential as a clinically useful biomarker in reporting disease status and predicting outcome in patients with CS and with CHD.

Keywords:
Neuroendocrine neoplasm of the small intestine
SI-NEN
Chromogranin A
Carcinoid syndrome
Carcinoid heart disease
Overall survival
Resumen
Introducción

La progresión hacia la afectación cardiaca en el síndrome carcinoide (SC) es difícil de predecir. En el presente análisis retrospectivo se evaluó el uso de la cromogranina A (CgA), un biomarcador ampliamente utilizado en el diagnóstico de los tumores neuroendocrinos (TNE), en el seguimiento del SC y en la progresión de la enfermedad.

Pacientes y métodos

Se incluyeron 108 pacientes con SC confirmado, seleccionados de un grupo de 351 pacientes con tumores neuroendocrinos del intestino delgado (TNE-ID). El 40% de pacientes tenían un TNE G1 bien diferenciado y un 60% un TNE G2 moderadamente diferenciado. Los niveles de CgA se determinaron en el momento del diagnóstico y durante el seguimiento en 84 pacientes, 27 de los cuales desarrollaron afectación cardiaca. La supervivencia global de los pacientes se evaluó mediante el método de Kaplan-Meier.

Resultados

Los pacientes con afectación cardiaca tuvieron una supervivencia global significativamente más corta que aquellos sin ella (67,22 frente a 73,03 meses). El análisis univariado y multivariado mostró que los niveles inicialmente altos de CgA y/o los niveles elevados de CgA durante la evolución se asocian de forma significativa con una menor supervivencia global en los pacientes con SC (p<0,05).

Conclusión

La CgA constituye un biomarcador clínicamente útil para evaluar la progresión de la enfermedad y la afectación cardiaca en pacientes con SC.

Palabras clave:
Tumores neuroendocrinos del intestino delgado
TNE-ID
Cromogranina A
Síndrome carcinoide
Enfermedad cardiaca carcinoide
Supervivencia global

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos